Illumina Inc. (ILMN)
NASDAQ: ILMNHealthcareDiagnostics & ResearchUSD
At close: Oct 7, 4:00 PM ET · Delayed 15 min
After hours: 270.00 +0.84%
ILMN stock chart
Technical analysisKey statistics
All statistics- Market cap
- $40.43B
- P/E (TTM)
- 49.96
- Forward P/E
- 43.83
- EPS (TTM)
- $5.36
- Dividend yield
- None
- 52-week range
- 88.00 – 309.35
- Day range
- 260.45 – 276.20
- Volume / Avg
- 2.83M / 2.66M
- Beta
- —
- Shares outstanding
- 151.00M
- Next earnings
- Oct 29, 2026
52-week range
ILMN stock today
On Oct 7, ILMN ended the session at $267.76, shedding $5.78 (2.11%), versus the S&P 500's 0.22% decline. At this level, ILMN sits near the top of its 52-week range of $88.00 to $309.35: 13.4% below the high, set on Oct 6, 2026 and 204.3% above the low. ILMN is up 107.1% year to date, outperforming the S&P 500 (+14.0%). Over the past 12 months, the stock has gained 180.9%.
At 50.0x trailing earnings, Illumina trades above the peer-group median of 33.3x. Its forward P/E of 43.8x is lower than the trailing multiple, which means analysts expect earnings to rise over the next year. Illumina's next earnings report is expected on Oct 29, 2026.
Summary generated from market data by MetaCap's automated system. Methodology
About Illumina
Company profileIllumina, Inc. provides sequencing- and array-based solutions for genetic and genomic analysis in the Americas, Europe, Greater China, the Asia Pacific, the Middle East, and Africa. The company offers sequencing- and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.
- Sector
- Healthcare
- Industry
- Diagnostics & Research
- CEO
- Mr. Jacob Thaysen Ph.D.
- Headquarters
- San Diego, CA
- Employees
- 8,600
- IPO year
- 2000
- Website
- illumina.com
Financial highlights
Full financialsIn fiscal 2025, Illumina generated $4.34 billion in revenue, down 0.7% from fiscal 2024, its first annual decline since 2024. Net income was $850.0 million, for a net margin of 19.6% versus a median of -25.8% in the prior 5 years. Gross margin was 66.1% (up from 65.4%) and operating margin 18.6%.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | $4.34B | $4.37B | $4.50B | $4.58B | $4.53B |
| Growth | -0.66% | -2.93% | -1.75% | +1.28% | +39.73% |
| Net income | $850.00M | $-1.22B | $-1.16B | $-4.40B | $762.00M |
| EPS (diluted) | $5.45 | $-7.69 | $-7.34 | $-28.00 | $5.04 |
Analyst forecast
ForecastConsensus (21 analysts)
buy
Avg. price target
$223.85-16.40%
- Strong buy 4
- Buy 7
- Hold 6
- Sell 2
- Strong sell 2
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Next report
- Oct 29, 2026
- EPS estimate
- $1.36
- Last reported (Q2 2026)
- Jul 31, 2026
- EPS actual vs est.
- $1.35 vs —
ILMN news
All ILMN newsIllumina peers
Healthcare sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| IQVIQVIA Holdings Inc. | 258.13 | -0.71% | $42.49B | vs ILMN |
| IDXXIDEXX Laboratories Inc. | 506.67 | -1.70% | $39.92B | vs ILMN |
| WATWaters Corporation | 436.18 | -0.06% | $42.83B | vs ILMN |
| AAgilent Technologies Inc. | 169.03 | -0.18% | $47.66B | vs ILMN |
| MTDMettler-Toledo International Inc. | 1,533.40 | +0.02% | $30.72B | vs ILMN |
| NTRANatera Inc. | 395.56 | -1.27% | $57.02B | vs ILMN |
| LHLabcorp Holdings Inc. | 312.09 | +0.12% | $25.31B | vs ILMN |
| DGXQuest Diagnostics Incorporated | 226.96 | -0.63% | $25.05B | vs ILMN |
Indexes, lists and sector
Index membership
Appears in lists
Illumina stock FAQ
What is Illumina's stock price today?
ILMN last traded at $267.76 as of Oct 7, 4:00 PM EDT, down 2.11% on the day. Prices are delayed at least 15 minutes.
Does Illumina pay a dividend?
No. Illumina does not currently pay a regular cash dividend.
When is Illumina's next earnings date?
Illumina is expected to report earnings on Thursday, October 29, 2026. Analysts expect EPS of $1.36.
What is ILMN's P/E ratio?
ILMN trades at a trailing P/E ratio of 49.96 and a forward P/E of 43.83, compared with a median of 33.3 for its closest peers.
Is Illumina in the S&P 500?
Yes. Illumina (ILMN) is a constituent of the S&P 500 index.
Who is Illumina's CEO?
Mr. Jacob Thaysen Ph.D. is the chief executive officer of Illumina Inc., which has about 8,600 employees.
Has ILMN ever split its stock?
Yes. The most recent ILMN stock split was a 1028-for-1000 split on Jun 25, 2024, one of 2 splits on record.